Market research
MINA.F Synlogic, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- 0.96
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- 0.96
About
About Synlogic, Inc
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Research context
Synlogic, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MINA.F discussion.
5 years, 7 months ago
Synlogic, Inc is currently in a long term uptrend where the price is trading 12.6% above its 200 day moving average.
From a valuation standpoint, the stock is 82.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 231.3.
Synlogic, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 14.0% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.8% to $-10M since the same quarter in the previous year.
Based on the above factors, Synlogic, Inc gets an overall score of 3/5.